ASPREE (ASPirin in Reducing Events in the Elderly) is a large study led by Monash University researchers, that will, for the first time, determine aspirin’s potential for reducing the risk of heart attack, stroke, dementia and certain cancers in people aged 70 and over. It will also determine if potential health benefits outweigh the risks of regular aspirin in this age group.
The trial aims to recruit 12,500 healthy older people from Australia and 6500 from the USA.
To date, ASPREE has over 1000 GP co-investigators on the project and so far, over 3600 Australian participants have enrolled in the trial.
Professor John McNeil, Head, School of Public Health and Preventive Medicine and the Principal Investigator for ASPREE said this important study relies on Australian participants to help answer a question which has troubled general practitioners for many years – should all healthy older people routinely use low dose aspirin?
“ASPREE engages local GPs and community health networks and together, with this study we are bringing medical research to the people rather than the other way around.
“I encourage healthy Australians, aged 70 years and over and in good health, to participate in this significant study which could potentially result in an improved quality of life,” said Professor McNeil.
Participants selected for the trial will be randomly assigned to take either a low-dose aspirin tablet or a placebo pill for a period of five years. Annual follow-ups will involve a number of health, clinical and other measurements.
The ASPREE study will be complemented by the CSIRO supported Healthy Ageing Biobank which will collect over 10,000 blood samples from healthy Australians to investigate factors that may contribute to healthy ageing.
Eligible Australians will be sent a letter from ASPREE on behalf of their GP. Alternatively, those who are interested in the study can call ASPREE directly on 1800 728 745.